Fig. 2.

9B8 Alleviates the Decrease in Cell Viability Induced by Interleukin (IL)-1βA. Cell viability was assessed following stimulation with IL-1β (10 ng/ml) and varying concentrations of 9B8 (0, 25, 50, 100, 200 μg/ml) at different time points. B. Cell viability following IL-1β (10 ng/ml) stimulation after pre-treatment with various concentrations of 9B8 (0, 25, 50, 100, 200 μg/ml). All experiments were conducted at least three times, and the data are presented as mean ± standard deviation. *p < 0.05, **p < 0.01, ***p < 0.001 ****p < 0.0001 compared with the IL-1β−treated groups.